Once a hybridoma has been obtained, it is possible to modify the monoclonal antibody to enhance its functionality. Some examples include isotype switching, chimerisation, and humanisation. This is done by cloning and sequencing variable region cDNAs and grafting select regions onto a suitable framework. The plasmid containing the modified genetic material is synthesized and the recombinant antibody is then produced by transient transfection using a mammalian expression system.
Innovagen provides a range of services for the designing and production of proteins and antibodies. These can be provided as stand-alone services or integrated in larger projects;.
Innovagen was founded in 1992. Since then we have been providing the research community with high quality research services and materials.
Postal address |
Innovagen AB SE-22370 Lund SWEDEN |
Telephone | |
Switchboard Fax | +46 46 286 20 60 +46 46 18 81 71 |
General information |
In order to provide you with the best online experience this website uses cookies. By using our website, you agree to our use of cookies. More information available here.